Zacks Research Downgrades DiaSorin (OTCMKTS:DSRLF) to Strong Sell

DiaSorin (OTCMKTS:DSRLF) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Thursday,Zacks.com reports.

A number of other analysts have also commented on DSRLF. Piper Sandler assumed coverage on DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating for the company. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. BNP Paribas Exane cut DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of DiaSorin in a report on Tuesday. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DiaSorin presently has a consensus rating of “Reduce”.

DiaSorin Stock Performance

Shares of OTCMKTS DSRLF opened at $85.56 on Thursday. DiaSorin has a twelve month low of $66.50 and a twelve month high of $100.00. The company has a 50 day moving average of $79.59 and a 200 day moving average of $76.58.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.